Evidence map›Paper›PMID 34490478›Full record

ArticleMolecular medicine reports2021

Lycium barbarum polysaccharide protects ARPE‑19 cells against H

Ran Liang, Qi Zhao, Qing Zhu, Xin He, Mingjun Gao, Yiru Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Modulatory effects ofOpen medicine (Warsaw, Poland) · 2025
    Article
  4. Frontiers in pharmacology · 2025
    Review
  5. Article
  6. International journal of ophthalmology · 2025
    Article
  7. Review
  8. Article
  9. Retinal ischemia-reperfusion injury and pretreatment withInternational journal of ophthalmology · 2024
    Article
  10. Distinct Role ofPharmaceuticals (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Oxidative medicine and cellular longevity · 2023
    Article
  13. Frontiers in aging neuroscience · 2023
    Article
  14. Article
  15. Effects ofMolecules (Basel, Switzerland) · 2022
    Review
  16. Supplementation ofNutrients · 2022
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ran Liang *Department of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Qi Zhao *Department of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Qing ZhuDepartment of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Xin HeDepartment of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Mingjun GaoDepartment of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Yiru WangDepartment of Ophthalmology, The Second Hospital of Dalian Medical University, Dalian, Liaoning 116021, P.R. China.
Second Affiliated Hospital of Dalian Medical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Age‑related macular degeneration (AMD) is a global health problem. Lycium barbarum polysaccharide (LBP), a traditional Chinese herbal medicine, has been proven to be effective against several eye diseases. However, only a few studies have investigated the effectiveness of LBP for AMD. In the present study, the human retinal epithelial cell line, ARPE‑19, was pretreated with LBP for 24 h before exposure to H

Indexed as

ApoptosisCell LineDrugs, Chinese HerbalHeme Oxygenase-1HumansMacular DegenerationNF-E2-Related Factor 2Oxidative StressProtective AgentsReactive Oxygen SpeciesDrugs, Chinese HerbalHeme Oxygenase-1HMOX1 protein, humanlycium barbarum polysaccharideNFE2L2 protein, humanNF-E2-Related Factor 2Protective AgentsReactive Oxygen Speciesage‑related macular degenerationLycium barbarum polysaccharidenuclear factor erythroid 2‑related factor 2/heme oxygenase‑1 pathwayoxidative stressretinal pigment epithelium

Identifiers

PMID34490478
PMCPMC8436232
OpenAlexW3196750701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.